Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 4 Results

Title
Intervention Indication Therapeutic Area Year Actions
Durvalumab and enfortumab vedotin with or without tremelimumab for muscle-invasive bladder cancer Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Enfortumab vedotin (ASG-22ME; Padcev) , Tremelimumab (CP-675206; CP-675 206) Bladder cancer Urological Cancer 2024 View  |  Download
Enfortumab vedotin for locally advanced or metastatic urothelial cancer Enfortumab vedotin (ASG-22ME; Padcev) Urothelial cancer Urological Cancer 2020 View  |  Download
Enfortumab vedotin with pembrolizumab for previously untreated locally advanced or metastatic urothelial cancer Enfortumab vedotin (ASG-22ME; Padcev) , Pembrolizumab (Keytruda; MK-3475) Urothelial cancer Urological Cancer 2022 View  |  Download
Enfortumab vedotin with pembrolizumab for treating bladder cancer Enfortumab vedotin (ASG-22ME; Padcev) , Pembrolizumab (Keytruda; MK-3475) Bladder cancer Urological Cancer 2023 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications